Adenoid Cystic Carcinoma Researchfoundation
Adenoid Cystic Carcinoma Researchfoundation maintains stable finances with no reported executive compensation.
EIN: 206745475 · Needham, MA · NTEE: H12 · Updated: 2026-03-28
| Metric | Value |
|---|---|
| Total Revenue | $1.1M |
| Total Expenses | $1.9M |
| Program Spending | 90% |
| CEO/Top Officer Pay | $2 |
| Net Assets | $2.5M |
| Transparency Score | 92/100 |
Is Adenoid Cystic Carcinoma Researchfoundation Legit?
Some Concerns
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
Adenoid Cystic Carcinoma Researchfoundation directs 90% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Adenoid Cystic Carcinoma Researchfoundation
Adenoid Cystic Carcinoma Researchfoundation (EIN: 206745475) is a nonprofit organization based in Needham, MA, classified under NTEE code H12. The organization reported total revenue of $1.1M and total assets of $2.3M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Adenoid Cystic Carcinoma Researchfoundation's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Adenoid Cystic Carcinoma Researchfoundation is a mid-size nonprofit that has been operating for 20 years, with 12 years of IRS 990 filings on record (2012–2023). Revenue has grown at a compound annual rate of 1.0%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $1.9M |
| Total Expenses | $1.9M |
| Surplus / Deficit | +$21K |
| Total Assets | $2.7M |
| Total Liabilities | $147K |
| Net Assets | $2.5M |
| Operating Margin | 1.1% |
| Debt-to-Asset Ratio | 5.5% |
| Months of Reserves | 17.2 months |
Financial Health Grade: A
In 2023, Adenoid Cystic Carcinoma Researchfoundation reported a surplus of $21K with revenue exceeding expenses, holds 17.2 months of operating reserves (strong position), has a debt-to-asset ratio of 5.5% (very low leverage).
Financial Trends
Over 12 years of filings (2012–2023), Adenoid Cystic Carcinoma Researchfoundation's revenue has grown at a compound annual growth rate (CAGR) of 1.0%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | +36.6% | +15.7% | +1.2% |
| 2022 | -42.9% | -21.9% | -15.1% |
| 2021 | +100.8% | +45.7% | +20.1% |
| 2020 | -42.6% | +15.9% | -1.5% |
| 2019 | +3.0% | -5.3% | +36.8% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 1200 |
| IRS Ruling Date | 2006 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Adenoid Cystic Carcinoma Researchfoundation with a Mission Score of 92 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 5%
- programs: 90%
- fundraising: 5%
According to IRS 990 filings, Adenoid Cystic Carcinoma Researchfoundation allocates its expenses as follows: admin: 5%, programs: 90%, fundraising: 5%. With 90% directed toward programs, this reflects a strong commitment to its charitable mission.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a surplus of $21K, with revenue exceeding expenses.
- Debt-to-asset ratio: 5.5%.
Executive Compensation Analysis
Executive compensation is reported as 0% across all available filings, indicating that no salaries or benefits are paid to officers, which is highly unusual for an organization of this size with assets exceeding $2 million.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of Adenoid Cystic Carcinoma Researchfoundation's IRS 990 filings:
- No specific breakdown of program, administrative, and fundraising expenses provided in the summary data, making it difficult to precisely verify spending efficiency ratios beyond the absence of officer compensation.
Strengths
The following positive indicators were identified for Adenoid Cystic Carcinoma Researchfoundation:
- Consistent financial reporting with 12 filings, demonstrating transparency.
- 0% reported officer compensation across all filings, indicating high resource allocation to mission.
- Positive trend in assets, growing from $1,563,125 in 201612 to $2,690,770 in 202312.
- Generally balanced revenue and expenses, with revenue often exceeding or closely matching expenses.
- Low liabilities relative to assets, indicating strong financial health.
Frequently Asked Questions about Adenoid Cystic Carcinoma Researchfoundation
Is Adenoid Cystic Carcinoma Researchfoundation a legitimate charity?
Adenoid Cystic Carcinoma Researchfoundation (EIN: 206745475) is a registered tax-exempt nonprofit based in Massachusetts. Our AI analysis gives it a Mission Score of 92/100. It has 12 years of IRS 990 filings on record. Total revenue: $1.1M. 1 red flag identified. 5 strengths noted. Financial health grade: A.
How does Adenoid Cystic Carcinoma Researchfoundation spend its money?
Adenoid Cystic Carcinoma Researchfoundation directs 90% of its spending to programs and services. Fundraising costs 5%. This exceeds the 65% industry benchmark.
Are donations to Adenoid Cystic Carcinoma Researchfoundation tax-deductible?
Adenoid Cystic Carcinoma Researchfoundation is registered as a tax-exempt nonprofit (EIN: 206745475). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
How much does the Adenoid Cystic Carcinoma Researchfoundation CEO make?
Adenoid Cystic Carcinoma Researchfoundation's highest-compensated officer earns $2 annually. The organization reported $1.1M in total revenue. Executive compensation data is disclosed in IRS 990 filings.
What percentage of Adenoid Cystic Carcinoma Researchfoundation's spending goes to programs?
Adenoid Cystic Carcinoma Researchfoundation directs 90% to programs, 5% to fundraising. This exceeds the 65% industry benchmark for efficient nonprofits.
How does Adenoid Cystic Carcinoma Researchfoundation compare to similar nonprofits?
With a transparency score of 92/100 (Excellent), Adenoid Cystic Carcinoma Researchfoundation is above average for NTEE category H12 nonprofits. The score reflects financial transparency, program spending efficiency, and governance quality based on IRS 990 data.
Where is Adenoid Cystic Carcinoma Researchfoundation located?
Adenoid Cystic Carcinoma Researchfoundation is headquartered in Needham, Massachusetts and files with the IRS under EIN 206745475. It is classified under NTEE code H12.
How many years of IRS 990 filings does Adenoid Cystic Carcinoma Researchfoundation have?
Adenoid Cystic Carcinoma Researchfoundation has 12 years of IRS 990 filings on record at NonprofitSpending. This extensive filing history provides a strong basis for evaluating long-term financial trends. The most recent filing shows $1.1M in total revenue.
Is Adenoid Cystic Carcinoma Researchfoundation a good charity?
Based on the provided data, the Adenoid Cystic Carcinoma Researchfoundation appears to be a very good charity. It demonstrates strong financial health, consistent asset growth, and notably, reports 0% officer compensation across all filings, suggesting a high dedication of resources to its mission.
How does the organization manage its expenses relative to revenue?
The organization generally manages its expenses well, with revenues often exceeding or closely matching expenses. For example, in 202312, revenue was $1,893,545 and expenses were $1,872,720. While there are years where expenses slightly exceeded revenue (e.g., 202212), the overall trend shows responsible financial management and asset growth.
What is the trend in the organization's assets?
The organization's assets have shown a positive growth trend over the years, increasing from $1,563,125 in 201612 to $2,690,770 in 202312, indicating financial stability and accumulation of resources.
Filing History
IRS 990 filing history for Adenoid Cystic Carcinoma Researchfoundation showing financial trends over 12 years of public records:
Over 12 years of IRS 990 filings (2012–2023), Adenoid Cystic Carcinoma Researchfoundation's revenue has grown by 11.9%, moving from $1.7M to $1.9M. Total assets decreased by 5.5% over the same period, from $2.8M to $2.7M. Total functional expenses rose by 35.9%, from $1.4M to $1.9M. In its most recent filing year (2023), Adenoid Cystic Carcinoma Researchfoundation reported a surplus of $21K, with revenue exceeding expenses. The organization holds $147K in liabilities against $2.7M in assets (debt-to-asset ratio: 5.5%), resulting in net assets of $2.5M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $1.9M | $1.9M | $2.7M | $147K | — | View 990 |
| 2022 | $1.4M | $1.6M | $2.7M | $137K | — | View 990 |
| 2021 | $2.4M | $2.1M | $3.1M | $608K | — | View 990 |
| 2020 | $1.2M | $1.4M | $2.6M | $438K | — | — |
| 2019 | $2.1M | $1.2M | $2.6M | $265K | — | View 990 |
| 2018 | $2.0M | $1.3M | $1.9M | $431K | — | View 990 |
| 2017 | $1.6M | $1.2M | $1.6M | $868K | — | View 990 |
| 2016 | $1.1M | $2.1M | $1.6M | $1.2M | — | View 990 |
| 2015 | $1.7M | $1.8M | $2.1M | $826K | — | View 990 |
| 2014 | $1.4M | $1.5M | $2.1M | $607K | — | View 990 |
| 2013 | $765K | $1.9M | $2.1M | $553K | — | View 990 |
| 2012 | $1.7M | $1.4M | $2.8M | $122K | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $1.9M, expenses of $1.9M, and assets of $2.7M (revenue +36.6% year-over-year).
- 2022: Revenue of $1.4M, expenses of $1.6M, and assets of $2.7M (revenue -42.9% year-over-year).
- 2021: Revenue of $2.4M, expenses of $2.1M, and assets of $3.1M (revenue +100.8% year-over-year).
- 2020: Revenue of $1.2M, expenses of $1.4M, and assets of $2.6M (revenue -42.6% year-over-year).
- 2019: Revenue of $2.1M, expenses of $1.2M, and assets of $2.6M (revenue +3.0% year-over-year).
- 2018: Revenue of $2.0M, expenses of $1.3M, and assets of $1.9M (revenue +27.5% year-over-year).
- 2017: Revenue of $1.6M, expenses of $1.2M, and assets of $1.6M (revenue +45.7% year-over-year).
- 2016: Revenue of $1.1M, expenses of $2.1M, and assets of $1.6M (revenue -34.2% year-over-year).
- 2015: Revenue of $1.7M, expenses of $1.8M, and assets of $2.1M (revenue +21.4% year-over-year).
- 2014: Revenue of $1.4M, expenses of $1.5M, and assets of $2.1M (revenue +79.9% year-over-year).
- 2013: Revenue of $765K, expenses of $1.9M, and assets of $2.1M (revenue -54.8% year-over-year).
- 2012: Revenue of $1.7M, expenses of $1.4M, and assets of $2.8M.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Adenoid Cystic Carcinoma Researchfoundation:
Data Sources and Methodology
This transparency report for Adenoid Cystic Carcinoma Researchfoundation is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.